More in-depth understanding of the biology of the CD137-CD137L co-stimulation system opens an opportunity to identify new prognostic biomarkers and the design of novel therapeutic approaches for advancing the management of SLE. The gene discussed is TNFRSF9; the disease is systemic lupus erythematosus.